Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 1.07 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 4:00pm Bid x Ask Size: N/A
Change: up arrow +0.0200 (+1.90%) Day's Range: 1.05 - 1.07
Prev Close: 1.0500 52wk Range: 0.53 - 2.10
Open: 1.0600 P/E (ttm): N/A
Volume: 125,450 EPS (ttm): -0.53
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
CEL SCI CORP Financials
Tue, 19 Aug 2014 17:04:10 GMT
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada
Tue, 19 Aug 2014 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* has added Centre Hospitalier Universitaire de Québec ’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America.
CEL SCI CORP Files SEC form 10-Q, Quarterly Report
Fri, 08 Aug 2014 20:15:39 GMT
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
Fri, 08 Aug 2014 20:10:00 GMT
[Business Wire] - CEL-SCI Corporation today reported financial results for the quarter ended June 30, 2014.
CEL SCI CORP Files SEC form 8-K, Change in Directors or Principal Officers
Thu, 07 Aug 2014 18:31:33 GMT
Cel-Sci's Enrollment Math Doesn't Add up
Fri, 01 Aug 2014 15:11:00 GMT
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial
Fri, 01 Aug 2014 12:45:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
Wed, 30 Jul 2014 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that the French Agency for the Safety of Health Products has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* in France.
CEL SCI CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Wed, 23 Jul 2014 15:36:56 GMT
CEL-SCI Has Been Cleared to Begin Patient Enrollment
Wed, 23 Jul 2014 12:01:00 GMT
[GlobeNewswire] - LOS ANGELES -- Yesterday morning, CEL-SCI Corporation (NYSE MKT:CVM) announced that Turkey's Ministry of Health had cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III ...
CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
Tue, 22 Jul 2014 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that Turkey’s Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI’s global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* .
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
Thu, 17 Jul 2014 12:45:00 GMT
[Business Wire] - VIENNA, Va.--(BUSINESSWIRE)-- CEL-SCI Corporation (NYSE MKT:CVM) today announced that Sri Lanka’s Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Sri Lanka. This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. CEL-SCI’s global pivotal Phase III clinical trial is the largest trial for head and neck cancer in the world. The trial, which already has over 220 patients enrolled, is assessing the Company’s investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer.
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
Thu, 17 Jul 2014 12:45:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that Sri Lanka’s Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* in Sri Lanka.
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
Tue, 15 Jul 2014 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that it has been awarded a Phase I Small Business Innovation Research grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases , which is part of the National Institutes of Health .
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference
Fri, 11 Jul 2014 13:00:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, announced today that Daniel Zimmerman, Ph.D., its Senior Vice President of Research, Cellular Immunology, delive
CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI’S Phase III Head and Neck Cancer Trial into Austria
Tue, 08 Jul 2014 12:15:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* .
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Tue, 03 Jun 2014 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
CEL-SCI receives approval to expand Phase III trial to U.K.
Mon, 02 Jun 2014 13:31:14 GMT
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
Mon, 02 Jun 2014 13:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted regulatory approval to begin the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* in the United Kingdom .
University of Cincinnati Cancer Institute’s Comprehensive Head and Neck Cancer Center Joins CEL-SCI’S Phase III Trial
Tue, 27 May 2014 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that the University of Cincinnati Cancer Institute is the latest medical center in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* .